Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as wel… Read more
Ocular Therapeutix Inc (OCUL) - Total Liabilities
Latest total liabilities as of December 2025: $153.75 Million USD
Based on the latest financial reports, Ocular Therapeutix Inc (OCUL) has total liabilities worth $153.75 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ocular Therapeutix Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Ocular Therapeutix Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ocular Therapeutix Inc Competitors by Total Liabilities
The table below lists competitors of Ocular Therapeutix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Joinn Laboratories(China)Co
SHG:603127
|
China | CN¥1.41 Billion |
|
CTP N.V
PINK:CTPVF
|
USA | $11.20 Billion |
|
Hang Lung Properties Limited
F:AOP
|
Germany | €78.29 Billion |
|
China Merchants Port Holdings Company Limited
PINK:CMHHF
|
USA | $50.72 Billion |
|
Glodon Software Co Ltd
SHE:002410
|
China | CN¥3.47 Billion |
|
Anywhere Real Estate Inc
NYSE:HOUS
|
USA | $4.22 Billion |
|
Shanghai DaZhong Public Utilities Group Co Ltd
SHG:600635
|
China | CN¥12.52 Billion |
|
Nicolet Bankshares Inc.
NYSE:NIC
|
USA | $7.93 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Ocular Therapeutix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ocular Therapeutix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ocular Therapeutix Inc (2012–2025)
The table below shows the annual total liabilities of Ocular Therapeutix Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $153.75 Million | +7.82% |
| 2024-12-31 | $142.59 Million | -11.40% |
| 2023-12-31 | $160.93 Million | +41.28% |
| 2022-12-31 | $113.91 Million | -2.55% |
| 2021-12-31 | $116.89 Million | -37.08% |
| 2020-12-31 | $185.77 Million | +125.53% |
| 2019-12-31 | $82.37 Million | +121.62% |
| 2018-12-31 | $37.17 Million | +26.92% |
| 2017-12-31 | $29.28 Million | +27.70% |
| 2016-12-31 | $22.93 Million | +10.68% |
| 2015-12-31 | $20.72 Million | +6.26% |
| 2014-12-31 | $19.50 Million | -75.20% |
| 2013-12-31 | $78.62 Million | +9.35% |
| 2012-12-31 | $71.90 Million | -- |